bioRxiv · 10.1101/260232
Development of photoactivatable drugs enables nicotinic optopharmacology
Abstract
Photoactivatable ( caged) pharmacological agents have revolutionized neuroscience but the palette of available ligands is limited. We describe a general method for caging tertiary amines using an unconventional quaternary ammonium linkage that is chemically stable and elicits a desirable red-shift in activation wavelength. A photoactivatable nicotine (PA-Nic) prepared using this strategy could be uncaged via 1- or 2-photon excitation, making it useful for optopharmacology experiments to study nicotinic acetylcholine receptors (nAChRs) in different experimental preparations and spatiotemporal scales.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Banala, S., Arvin, M. C., Bannon, N. M., Jin, X.-T., Wang, Y., Zhao, G., Marshall, J. J., Gee, K. R., Wokosin, D. L., Contractor, A., Henry, L. A., Kozorovitskiy, Y., Drenan, R. M., Lavis, L. D.. 2018-02-05. Development of photoactivatable drugs enables nicotinic optopharmacology. https://doi.org/10.1101/260232
Cite the original work for its findings. Save a collection to share your selection of sources.